23 March 2020
In this article written by Managing IP, Mathys & Squire partner Martin MacLean provides his expert opinion on vaccine development during the midst of the COVID-19 global pandemic.
Martin explains that vaccine development in the midst of a global pandemic is difficult because by the time scientists have marketing authorisation for their vaccine, the virus might have already swept through a population.
In that event, companies would have invested millions of dollars and have little guarantee for a return on their investment.
Speaking to Managing IP, Martin comments: “The patent application process takes several years to complete, and one can only enforce a granted patent. Heaven knows how one would optimally enforce a vaccine patent during a pandemic such as coronavirus.”
“In such scenarios, governments may need rapid access to the patented technology and can’t be held to ransom. As a result, licence negotiations would become a second order consideration, and might not conclude as favourably as they would in a freely negotiated environment.”
To read the full article by Managing IP, please click here (login required).
Sign up to our mailing list to receive Mathys Matters, our monthly newsletter covering the latest IP news, industry insights, events and case law.
If you are interested in receiving quarterly newsletters relevant to our core sector groups - IT & engineering ('Inside Wires') and life sciences & chemistry ('Under the Microscope') - please select your preference(s) below:
Please select your practice area(s) of interest: